NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Septerna, Inc. ( SEPN ) Reports Q3 Loss, Misses Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -147.37% and -71.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics ( IOVA ) Reports Q3 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +13.79% and -4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Moderna ( MRNA ) : Can Its 13.9% Jump Turn into More Strength?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
San Francisco is making a comeback. So are these stocks from the City by the Bay
CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.
Arcturus Therapeutics ( ARCT ) Moves 7.7% Higher: Will This Strength Last?
Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Strength Seen in Septerna, Inc. ( SEPN ) : Can Its 7.0% Jump Turn into More Strength?
Septerna, Inc. (SEPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Options Traders Betting on a Big Move in Septerna Stock?
Investors need to pay close attention to SEPN stock based on the movements in the options market lately.
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside - Septerna ( NASDAQ:SEPN )
HC Wainwright gives Septerna a Buy rating and $26 price target citing multiple upcoming catalysts. Septerna trades below cash value despite a Novo Nordisk partnership and a promising drug pipeline. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Hilton Worldwide Holdings ( NYSE:HLT ) , Choice Hotels Intl ( NYSE:CHH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Chardan Capital analyst Keay Nakae initiated coverage on Monopar Therapeutics Inc.
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
5 Single-Stock ETFs That Doubled in a Month
We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
Does Septerna, Inc. ( SEPN ) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges ...
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie
Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.
3 Stocks That Will Profit From Trump's Drug Price Cut - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Trump's new Executive Order takes aim at high drug prices. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.
3 Stocks That Will Profit From Trump's Drug Price Cut - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Trump's new Executive Order takes aim at high drug prices. Here are three that are poised to profit regardless of DC politics. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role - Novo Nordisk ( NYSE:NVO )
Novo Nordisk CEO Lars Fruergaard Jørgensen to step down amid board and market pressure. Despite leadership changes, the company maintains its strategy. Get Matt Maley's top trade setups for a tariff-driven market, live this Wednesday at 6 PM ET. Reserve your free spot now.
Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals
Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
Dow Edges Higher; US Crude Oil Inventories Increase - Cellebrite DI ( NASDAQ:CLBT ) , Global E Online ( NASDAQ:GLBE )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.08% to 42,172.43 while the NASDAQ gained 0.74% to 19,151.42. The S&P 500 also rose, gaining, 0.24% to 5,900.93. Communication services shares jumped by 1.6% ...
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Novo Nordisk ( NYSE:NVO ) , Septerna ( NASDAQ:SEPN )
Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1, GIP, and glucagon receptors, for obesity and type 2 diabetes therapies.
Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings - Accelerate Diagnostics ( NASDAQ:AXDX ) , HWH International ( NASDAQ:HWH )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.19% to 42,218.65 while the NASDAQ gained 0.65% to 19,133.96. The S&P 500 also rose, gaining, 0.29% to 5,903.54.
Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. ( SEPN ) : Here's What You Should Know
The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 207.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Applied Optoelectronics ( NASDAQ:AAOI ) , Bit Origin ( NASDAQ:BTOG )
Shares of Rubrik, Inc. RBRK rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates. Rubrik reported quarterly losses of 61 cents per share, which beat the analyst consensus ...
SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm - Septerna ( NASDAQ:SEPN )
NEW YORK, Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. ( "Septerna" or the "Company" ) SEPN on behalf of Septerna stockholders.
Kirby McInerney LLP Announces Investigation Against Septerna, Inc. ( SEPN ) on Behalf of Investors - Septerna ( NASDAQ:SEPN )
NEW YORK, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. ( "Septerna" or the "Company" ) SEPN. The investigation concerns whether Septerna and/or certain of its officers have violated the federal securities laws ...
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.
Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm - Septerna ( NASDAQ:SEPN )
LOS ANGELES, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Septerna, Inc. ( "Septerna" or "the Company" ) SEPN investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors.
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings - PainReform ( NASDAQ:PRFX ) , Fluor ( NYSE:FLR )
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Tuesday. The Dow traded down 0.38% to 44,378.28 while the NASDAQ fell 0.47% to 19,932.75. The S&P 500 also fell, dropping, 0.16% to 6,105.15. Energy shares jumped by 1.8% on Tuesday.
US Stocks Mixed; NY State Business Activity Rises In February - Healthcare Triangle ( NASDAQ:HCTI ) , Bio-Path Hldgs ( NASDAQ:BPTH )
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.24% to 44,440.80 while the NASDAQ rose 0.26% to 20,078.31. The S&P 500 also rose, gaining, 0.11% to 6,121.11.
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket - Acacia Research ( NASDAQ:ACTG ) , Aclarion ( NASDAQ:ACON )
Shares of Twilio Inc. TWLO rose sharply in today's pre-market trading after the company provided preliminary financial results for the fourth quarter. After the market close on Thursday, Twilio introduced new financial expectations in a regulatory filing.
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - AnaptysBio ( NASDAQ:ANAB ) , Associated Cap Gr ( NYSE:AC )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday. Shares of Progress Software Corporation PRGS fell sharply in today's pre-market trading after the company issued first-quarter EPS guidance below estimates.
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - AnaptysBio ( NASDAQ:ANAB ) , Associated Cap Gr ( NYSE:AC )
Shares of Netflix, Inc. NFLX rose sharply in today's pre-market trading as the company reported stronger-than-expected fourth-quarter financial results. Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year.
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - Septerna ( NASDAQ:SEPN )
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Septerna, Inc. SEPN, a clinical-stage biotech company pioneering a new era of G protein-coupled receptor ( GPCR ) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer.
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd ...
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Septerna ( NASDAQ:SEPN )
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd ...
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases ...
